The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
The role of nanotechnology in the treatment of viral infections
Open accessAbstract
Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery. These are predominantly due to the particle size (which affects bioavailability and circulation time), large surface area to volume ratio (enhanced solubility compared to larger particles), tunable surface charge of the particle with the possibility of encapsulation, and large drug payloads that can be accommodated. These properties, which are unlike bulk materials of the same compositions, make nanoparticulate drug delivery systems ideal candidates to explore in order to achieve and/or improve therapeutic effects. This review presents a broad overview of the application of nanosized materials for the treatment of common viral infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–257 of 257
Activation of Latent HIV Using Drug-Loaded Nanoparticles
Kovochich, M., Marsden, M. D., & Zack, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018270 · Cited by 88
Development of a nanoparticle-based influenza vaccine using the PRINT® technology
Galloway, A. L., Murphy, A., DeSimone, J. M., Di, J., Herrmann, J. P., Hunter, M. E., Kindig, J. P., Malinoski, F. J., Rumley, M. A., Stoltz, D. M., et al. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.001 · Cited by 87
CNS reservoirs for HIV: implications for eradication
Hellmuth, J. M., Valcour, V., & Spudich, S. (2015) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30489-1 · Cited by 87
Sarmento, B. F. C. C., Gomes, M. J., & das Neves, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s45886 · Cited by 84
Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells
Bose, S., Basu, M., & Banerjee, A. K. (2004) · Journal of Virology · doi:10.1128/jvi.78.15.8146-8158.2004 · Cited by 82
Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs
Chiodo, F., Marradi, M., Calvo, J., Yuste, E., & Penadés, S. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.136 · Cited by 79
Nanoparticle-based artificial RNA silencing machinery for antiviral therapy
Wang, Z., Liu, H., Yang, S. H., Wang, T., Liu, C., & Cao, Y. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207766109 · Cited by 76
Nanotechnology: A magic bullet for HIV AIDS treatment
Kumar, L., Verma, S., Prasad, D. N., Bhardwaj, A., Vaidya, B., & Jain, A. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.883400 · Cited by 76
Cohen, C. R., Brown, J., Moscicki, A., Bukusi, E. A., Paull, J. R., Price, C. F., & SHIBOSKI, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016258 · Cited by 74
Recent trends on hydrogel based drug delivery systems for infectious diseases
Vashist, A., Kaushik, A. K., Vashist, A., Jayant, R. D., Tomitaka, A., Ahmad, S., Gupta, Y. K., & Nair, M. (2016) · Biomaterials Science · doi:10.1039/c6bm00276e · Cited by 74
Wang, J., Feng, S., Wang, S., & Chen, Z.-Y. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.026 · Cited by 69
Jung, J. H., Park, B. H., Oh, S. J., Choi, G., & Seo, T. S. T. S. (2014) · Lab on a Chip · doi:10.1039/c4lc01033g · Cited by 69
Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
Chaowanachan, T., Krogstad, E. A., Ball, C. S., & Woodrow, K. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061416 · Cited by 68
Enhanced dermal delivery of acyclovir using solid lipid nanoparticles
Jain, S., Mistry, M. A., & Swarnakar, N. K. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0036-0 · Cited by 65
Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications
Arias, J. L., López-Viota, M., Ruíz, M. A., López-Viota, M., & Delgado, Á. V. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.02.028 · Cited by 65
Zeng, P., Xu, Y. F., Zeng, C., Ren, H., & Peng, M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.053 · Cited by 62
Moscicki, A., Kaul, R., Ma, Y., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823f2aeb · Cited by 61
Rodriguez, B. A., Asmuth, D. M., Matining, R. M., Spritzler, J., Jacobson, J. M., Mailliard, R. B., Li, X.-D., Martínez, A. I., Tenorio, A. R., Lori, F., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182a99590 · Cited by 58
Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy
Adesina, S. K., & Akala, E. O. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00335 · Cited by 58
Biomimetic and Bioinspired Nanoparticles for Targeted Drug Delivery
Gagliardi, M. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0013 · Cited by 58
Saleh, T., Bolhassani, A., Shojaosadati, S. A., & Aghasadeghi, M. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.015 · Cited by 57
Bastian, A. R., Nangarlia, A., Bailey, L. D., Holmes, A. P., Sundaram, R. V. K., Ang, C. G., Moreira, D. R. M., Freedman, K. J., Duffy, C., Contarino, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608315 · Cited by 57
Raghuwanshi, D., Mishra, V., Suresh, M. R., & Kaur, K. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.036 · Cited by 55
Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer
Misumi, S., Masuyama, M., Takamune, N., Nakayama, D., Mitsumata, R., Matsumoto, H., Urata, N., Takahashi, Y., Muneoka, A., Sukamoto, T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802928 · Cited by 53
Dwivedi, V., Manickam, C., Binjawadagi, B., & Renukaradhya, G. J. (2013) · Veterinary Microbiology · doi:10.1016/j.vetmic.2013.04.029 · Cited by 53
Skiadopoulos, M. H., Surman, S. R., Riggs, J. M., Örvell, C., Collins, P. L., & Murphy, B. R. (2002) · Virology · doi:10.1006/viro.2002.1415 · Cited by 50
de Oliveira, M. P., Garcion, E., Venisse, N., Benoît, J., Couet, W. R., & Olivier, J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7147-6 · Cited by 50
Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview
Mignani, S. M., & Majoral, J. (2013) · New Journal of Chemistry · doi:10.1039/c3nj00300k · Cited by 46
Nanomedicines for Treatment of Viral Diseases
Mehendale, R., Joshi, M. D., & Patravale, V. B. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013005469 · Cited by 45
Jiang, Y., Cao, S., Bright, D. K., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00544 · Cited by 45
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection
DeMarino, C., Schwab, A., Pleet, M. L., Mathiesen, A. H., Friedman, J. M., El‐Hage, N., & Kashanchi, F. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9692-7 · Cited by 45
Measuring and modelling cell-to-cell variation in uptake of gold nanoparticles
Jeynes, J. C. G., Jeynes, C., Merchant, M. J., & Kirkby, K. J. (2013) · The Analyst · doi:10.1039/c3an01406a · Cited by 43
Esser‐Nobis, K., Harak, C., Schult, P., Kusov, Y., & Lohmann, V. (2015) · Hepatology · doi:10.1002/hep.27847 · Cited by 42
Advancements in nano-enabled therapeutics for neuroHIV management
Kaushik, A. K., Jayant, R. D., & Nair, M. G. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s109943 · Cited by 41
Duan, L., Yan, Y., Liu, J., Wang, B., Li, P., Hu, Q., & Chen, W. (2016) · Scientific Reports · doi:10.1038/srep24867 · Cited by 38
Ramyadevi, D., Rajan, K. S., VedhaHari, B. N., Kandasamy, R., & Natesan, S. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.06.022 · Cited by 38
Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
Glass, J. J., Kent, S. J., & Rose, R. D. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1141054 · Cited by 37
Varanda, L. C., Imaizumi, M., dos Santos, F. J., & Jafelicci, M. (2008) · IEEE Transactions on Magnetics · doi:10.1109/tmag.2008.2002250 · Cited by 36
The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics
Shafagati, N., Patanarut, A., Luchini, A., Lundberg, L., Bailey, C., Petricoin, E. F., Liotta, L. A., Narayanan, A., Lepene, B. S., & Kehn‐Hall, K. (2014) · Pathogens and Disease · doi:10.1111/2049-632x.12136 · Cited by 36
Kuntworbe, N., Martini, N. D., Shaw, J., & Al‐Kassas, R. (2012) · Drug Development Research · doi:10.1002/ddr.21010 · Cited by 34
Enhanced Antiviral Activity of Acyclovir Loaded into Nanoparticles
Cavalli, R., Donalisio, M., Bisazza, A., Civra, A., Ranucci, E., Ferruti, P., & Lembo, D. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391858-1.00001-0 · Cited by 34
Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
Abián, O., Vega, S., Sancho, J., & Velázquez‐Campoy, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069773 · Cited by 33
New pharmacological approaches to a functional cure of hepatitis B
Seto, W., & Yuen, M. (2016) · Clinical Liver Disease · doi:10.1002/cld.577 · Cited by 33
Moon, J.-S., Lee, S., Han, S.-H., Kim, E., Cho, H., Lee, W., Kim, M. K., Kim, T.-E., Park, H., Rhee, J., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.02.015 · Cited by 32
Lockhat, H. A., Silva, J. R. A., Alves, C. N., Govender, T., Lameira, J., Maguire, G. E. M., Sayed, Y., & Kruger, H. G. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12690 · Cited by 29
Self-citationShell cross-linked polymeric micelles as camptothecin nanocarriers for anti-HCV therapy
Jiménez‐Pardo, I., González‐Pastor, R., Lancelot, A., Claveria‐Gimeno, R., Velázquez‐Campoy, A., Abian, O., Ros, M. B., & Sierra, T. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500094 · Cited by 28
Nanotechnology applications to HIV vaccines and microbicides
Mohapatra, S. S., Boyapalle, S., & Mohapatra, S. (2012) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.93764 · Cited by 23
Uddin, M. N., Kouzi, S. A., & Hussain, M. D. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3rs3v · Cited by 22
Caucheteux, S. M., Mitchell, J. P., Ivory, M. O., Hirosue, S., Hakobyan, S., Dolton, G. M., Ladell, K., Miners, K. L., Price, D. A., Kan‐Mitchell, J., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.01.033 · Cited by 22
Laing, P., Bacon, A. K., McCormack, B., Gregoriadis, G., Frisch, B., & Schuber, F. J. (2006) · Journal of Liposome Research · doi:10.1080/08982100600880432 · Cited by 21
Giezeman‐Smits, K. M., Nauta, J. J. P., de Bruijn, I. A., & Palache, A. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.008 · Cited by 19
Surface-modified protein nanospheres as potential antiviral agents
Baram‐Pinto, D., Shukla, S., Richman, M., Gedanken, A., Rahimipour, S., & Sarid, R. (2012) · Chemical Communications · doi:10.1039/c2cc33448h · Cited by 17
Potential inhibition of HIV-1 encapsidation by oligoribonucleotide–dendrimer nanoparticle complexes
Parboosing, R., Chonco, L., de la Mata, J., Govender, T., Maguire, G. E. M., & Kruger, G. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s114446 · Cited by 16
Self-citationClinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis
Batdelger, D., Dandii, D., Yagaanbuyant, D., Erdenetsogt, E., Oyunbileg, J., Tsend, N., Bayarmagnai, B., Jirathitikal, V., & Bourinbaiar, A. S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787846793 · Cited by 15
Core‐Shell Nanocatalysts Obtained in Reverse Micelles: Structural and Kinetic Aspects
Tojo, C., Buceta, D., & López-Quintela, M. A. (2015) · Journal of Nanomaterials · doi:10.1155/2015/601617 · Cited by 5
Advanced Nano-Materials for Biomedical Applications
Chauhan, A., Negi, A., Kashyap, R., Kirti, K., Sharma, R. K., & Chaudhary, G. R. (2023) · Biomedical materials for multi-functional applications · doi:10.1007/978-981-99-6286-0_2 · Cited by 5
Nanotechnology in Controlling Infectious Disease
Amin, R. (2011) · Science Publishers eBooks · doi:10.1201/b11076-10 · Cited by 2
Cited by
Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic
Weiss, C., Carriere, M., Fusco, L., Capua, I., Regla-Nava, J. A., Pasquali, M., Scott, J. A., Vitale, F., Unal, M. A., Mattevi, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03697 · Cited by 601
Metal Oxide Nanoparticles as Biomedical Materials
Nikolova, M. P., & Chavali, M. S. (2020) · Biomimetics · doi:10.3390/biomimetics5020027 · Cited by 510
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
A review on MnZn ferrites: Synthesis, characterization and applications
Thakur, P., Chahar, D., Taneja, S., Bhalla, N., & Thakur, A. (2020) · Ceramics International · doi:10.1016/j.ceramint.2020.03.287 · Cited by 451
Application of Light Scattering Techniques to Nanoparticle Characterization and Development
Carvalho, P. M., Felício, M. R., Santos, N. C., Gonçalves, S., & Domingues, M. M. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00237 · Cited by 402
Metadata
- Authors
- Singh, L., Kruger, H. G., Maguire, G. E. M., Govender, T., & Parboosing, R.
- Venue
- Therapeutic Advances in Infectious Disease
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 4
- Issue
- 4
- Pages
- 105-131
- ISSN
- 2049-9361 (ISSN-L)
- 2049-937X
- OpenAlex
- W2735723920
- Cited by
- 360
- References
- 257
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.